MONDAY July 14, 2008 (foodconsumer.org) -- A study found
Amgen Inc's experimental drug denosumab reduced the risk of osteoporosis and
fracture in men receiving treatments for prostate cancer that can cause bone
loss, the company said Monday.
The study of more than 1,400 men with non-metastatic
prostate cancer undergoing androgen deprivation treatment showed denosumab
rendered greater increase in bone mineral density than a placebo. The increase
was seen at the Lumbar spine and non-vertebral sites.
Additionally, denosumab
cut the incidence of new vertebral
fractures in men receiving the drug by 50 percent compared to that for men who
did not received the drug.
Incidence of non-vertebral fractures in the denosumab
patients was also reduced, but not statistically significantly.
Side effects seem minimal.
About 6 percent of denosumab patients developed serious infections in
the study compared to 5 percent of those receiving a placebo.
But according to Reuters, some early trials
showed greater risk of side effects.
Disclaimer: What's published on this website should be considered opinions of respective writers only and foodconsumer.org which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only.
The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals.
Foodconsumer.org encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.
